In a phase I trial followed by a phase I/II trial, lorlatinib was administered at the dose of 100 mg once-a-day to 21 TKI treatment-naïve patients and 40 crizotinib-treated patients, diagnosed with a ROS1-positive NSCLC [62,63,64,65]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.